SCHEMBL5403002

SCHEMBL5403002

Cc1[nH]c(C=O)c(C)c1C(=O)N1CCN(CCO)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.44
POLB P06746 3/20 0.41
ALDH1A1 P00352 3/20 0.41
TSHR P16473 3/20 0.39
ALOX15 P16050 1/20 0.39
LMNA P02545 2/20 0.37
MAPT P10636 2/20 0.37
FLT1 P17948 1/20 0.37
KDR P35968 1/20 0.37
KMT2A Q03164 4/20 0.37
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 3/20 0.36
HPGD P15428 1/20 0.36
PARP1 P09874 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4405167 0.84 HRH4 (0.42) TSHRALOX15LMNAMAPTFLT1
SCHEMBL16466885 0.80 HPGD (0.55) POLBALDH1A1TSHRALOX15LMNA
SCHEMBL5402361 0.79 HRH4 (0.40) ALDH1A1TSHRALOX15LMNAMAPT
SCHEMBL5403365 0.77 TSHR (0.58) POLBALDH1A1TSHRALOX15FLT1
SCHEMBL13195269 0.76 TSHR (0.56) POLBALDH1A1TSHRALOX15FLT1
SCHEMBL31726674 0.73 KDR (0.55) FLT1KDRKMT2AMEN1MET
SCHEMBL7114644 0.72 KMT2A (0.36) POLBALDH1A1TSHRALOX15LMNA
SCHEMBL31727295 0.72 AKR1C3 (0.46) AKR1C3POLBALDH1A1TSHRMAPT
SCHEMBL7114640 0.72 KMT2A (0.36) POLBALDH1A1TSHRALOX15LMNA
SCHEMBL688926 0.71 PDGFRB (0.41) AKR1C3POLBALDH1A1LMNAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025233641-A1 NOVEL PHOTOINDUCIBLE KINASE INHIBITORS FOR TREATING PROLIFERATIVE AND VASOPROLIFERATIVE DISEASES SEMMELWEIS EGYETEM (HU) 2025-11-13 WO disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) SUGEN, INC. 2004-12-30 US disclosed
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors DMPK, MAP3K20, PHKG1 AKR1C3 1865/4885POLB 3394/4885ALDH1A1 3457/4885
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) CHEK2, CHEK1, ATM AKR1C3 3910/4885POLB 393/4885ALDH1A1 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.